CYP4F11
Basic information
Region (hg38): 19:15912367-15934867
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP4F11 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 41 | 44 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 41 | 3 | 0 |
Variants in CYP4F11
This is a list of pathogenic ClinVar variants found in the CYP4F11 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-15913803-G-A | not specified | Uncertain significance (Feb 16, 2023) | ||
19-15913811-C-T | not specified | Uncertain significance (Oct 13, 2023) | ||
19-15913820-G-A | not specified | Uncertain significance (Nov 09, 2023) | ||
19-15913836-T-A | not specified | Uncertain significance (Jul 06, 2021) | ||
19-15913836-T-C | not specified | Likely benign (Mar 18, 2024) | ||
19-15913844-T-A | not specified | Uncertain significance (Oct 10, 2023) | ||
19-15913892-G-A | not specified | Likely benign (Feb 05, 2024) | ||
19-15914317-G-A | not specified | Uncertain significance (Jan 20, 2023) | ||
19-15914326-A-G | not specified | Uncertain significance (Dec 12, 2023) | ||
19-15914330-A-C | not specified | Uncertain significance (Oct 27, 2023) | ||
19-15914357-T-C | not specified | Uncertain significance (May 23, 2024) | ||
19-15914383-T-C | not specified | Uncertain significance (Feb 28, 2024) | ||
19-15914385-G-A | not specified | Likely benign (Apr 01, 2024) | ||
19-15914387-C-A | not specified | Uncertain significance (Nov 14, 2023) | ||
19-15914612-G-A | not specified | Uncertain significance (Feb 28, 2023) | ||
19-15914774-C-T | not specified | Likely benign (Mar 30, 2024) | ||
19-15914828-C-T | not specified | Uncertain significance (Mar 29, 2024) | ||
19-15922058-C-T | not specified | Uncertain significance (Mar 28, 2022) | ||
19-15922059-G-A | not specified | Uncertain significance (Aug 22, 2023) | ||
19-15922059-G-T | not specified | Uncertain significance (May 05, 2023) | ||
19-15922088-C-T | not specified | Uncertain significance (Oct 29, 2021) | ||
19-15922135-C-G | not specified | Uncertain significance (Jun 17, 2024) | ||
19-15922422-A-T | not specified | Uncertain significance (Feb 14, 2023) | ||
19-15923877-C-T | not specified | Uncertain significance (Dec 15, 2022) | ||
19-15923878-A-C | not specified | Uncertain significance (Jan 26, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CYP4F11 | protein_coding | protein_coding | ENST00000402119 | 12 | 22501 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.47e-21 | 0.000364 | 125525 | 0 | 223 | 125748 | 0.000887 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.40 | 395 | 324 | 1.22 | 0.0000197 | 3442 |
Missense in Polyphen | 104 | 86.563 | 1.2014 | 997 | ||
Synonymous | -1.43 | 152 | 131 | 1.16 | 0.00000801 | 1016 |
Loss of Function | -0.584 | 30 | 26.7 | 1.12 | 0.00000130 | 287 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00348 | 0.00347 |
Ashkenazi Jewish | 0.000199 | 0.000198 |
East Asian | 0.000545 | 0.000544 |
Finnish | 0.000602 | 0.000601 |
European (Non-Finnish) | 0.000648 | 0.000642 |
Middle Eastern | 0.000545 | 0.000544 |
South Asian | 0.000654 | 0.000653 |
Other | 0.00327 | 0.00326 |
dbNSFP
Source:
- Function
- FUNCTION: Omega-hydroxylase that oxidizes a variety of structurally unrelated compounds, including fatty acids and xenobiotics. Plays a key role in vitamin K catabolism by mediating omega-hydroxylation of vitamin K1 (phylloquinone), and menaquinone-4 (MK-4), a form of vitamin K2. Hydroxylation of phylloquinone and MK-4 probably regulates blood coagulation (PubMed:24138531). Catalyzes omega-hydroxylation of 3-hydroxy fatty acids, such as 3-hydroxypalmitate, 3-hydroxyoleate, 3- hydroxyarachidonate, and 3-hydroxystearate (PubMed:18065749, PubMed:19932081). Oxidizes drugs such as erythromycin, benzphetamine, ethylmorphine, chlorpromazine and imipramine (PubMed:15364545). {ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:18065749, ECO:0000269|PubMed:19932081, ECO:0000269|PubMed:24138531}.;
- Pathway
- Oxidation by Cytochrome P450;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;Metabolism of lipids;Synthesis of Leukotrienes (LT) and Eoxins (EX);Arachidonic acid metabolism;Tyrosine metabolism;Fatty acids;Eicosanoids;Androgen and estrogen biosynthesis and metabolism;Miscellaneous substrates;Cytochrome P450 - arranged by substrate type;Leukotriene metabolism;Biological oxidations;Metabolism;Fatty acid metabolism;Linoleate metabolism;C21-steroid hormone biosynthesis and metabolism;Xenobiotics metabolism;Tryptophan degradation;Arachidonic acid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.136
Intolerance Scores
- loftool
- 0.189
- rvis_EVS
- -0.64
- rvis_percentile_EVS
- 16.74
Haploinsufficiency Scores
- pHI
- 0.121
- hipred
- N
- hipred_score
- 0.139
- ghis
- 0.441
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.152
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cyp4f40
- Phenotype
Gene ontology
- Biological process
- fatty acid metabolic process;inflammatory response;blood coagulation;menaquinone catabolic process;phylloquinone catabolic process;vitamin K catabolic process;oxidation-reduction process
- Cellular component
- endoplasmic reticulum membrane;integral component of membrane;organelle membrane
- Molecular function
- monooxygenase activity;fatty acid binding;iron ion binding;oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen;heme binding